Benefit of antiretroviral therapy on survival of human immunodeficiency virus-infected patients admitted to an intensive care unit

被引:77
|
作者
Croda, Julio [1 ,2 ]
Croda, Mariana Garcia
Neves, Alan [1 ]
dos Santos, Sigrid De Sousa [1 ]
机构
[1] Univ Sao Paulo, Infect & Parasit Dis Div, Lab Pathol Transmissible Dis, BR-05508 Sao Paulo, Brazil
[2] Univ Sao Paulo, Dept Pathol, Hosp Clin, Fac Med, BR-05508 Sao Paulo, Brazil
关键词
intensive care; human immunodeficiency virus; acquired immunodeficiency syndrome; antiretroviral therapy; prognostic factors; critical care; mortality; PNEUMOCYSTIS-CARINII-PNEUMONIA; HIV-INFECTION; PROGNOSTIC-FACTORS; PULMONARY COMPLICATIONS; HOSPITALIZED-PATIENTS; BACTERIAL PNEUMONIA; NATURAL-HISTORY; ICU SUPPORT; ERA; OUTCOMES;
D O I
10.1097/CCM.0b013e31819da8c7
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective: To evaluate the impact of antiretroviral therapy (ART) and the prognostic factors for in-intensive care unit (ICU) and 6-month mortality in human immunodeficiency virus (HIV)-infected patients. Design: A retrospective cohort study was conducted in patients admitted to the ICU from 1996 through 2006. The follow-up period extended for 6 months after ICU admission. Setting: The ICU of a tertiary-care teaching hospital at the Universidade de Sao Paulo, Brazil. Participants: A total of 278 HIV-infected patients admitted to the ICU were selected. We excluded ICU readmissions (37), ICU admissions who stayed less than 24 hours (44), and patients with unavailable medical charts (36). Outcome Measure: In-ICU and 6-month mortality. Main Results: Multivariate logistic regression analysis and Cox proportional hazards models demonstrated that the variables associated with in-ICU and 6-month mortality were sepsis as the cause of admission (odds ratio [OR] = 3.16 [95% confidence interval [CI] 1.65-6.06]); hazards ratio [HR] = 1.37 [95% Cl 1.01-1.88)), an Acute Physiology and Chronic Health Evaluation 11 score >19 [OR = 2.81 (95% CI 1.57-5.04); HR = 2.18 (95% CI 1.62-2.94)], mechanical ventilation during the first 24 hours [OR = 3.92 (95% CI 2.20-6.96); HR = 2.25 (95% CI 1.65-3.07)], and year of ICU admission [OR = 0.90 (95% CI 0.81-0.99); HR = 0.92 [95% CI 0.87-0.97)]. CD4 T-cell count <50 cells/mm(3) Was only associated with ICU mortality [OR = 2.10 (95% Cl 1.17-3.76)]. The use of ART in the ICU was negatively predictive of 6-month mortality in the Cox model [HR = 0.50 (95% CI 0.35-0.71)], especially if this therapy was introduced during the first 4 days of admission to the ICU [HR = 0.58 (95% CI 0.41-0.83)]. Regarding HIV-infected patients admitted to ICU without using ART, those who have started this treatment during ICU, stay presented a better prognosis when time and potential confounding factors were adjusted for [HR 0.55 (95% CI 0.31-0.98)]. Conclusions: The ICU outcome of HIV-infected patients seems to be dependent not only on acute illness severity, but also on the administration of antiretroviral treatment. (Crit Care Med 2009; 37: 1605-1611)
引用
收藏
页码:1605 / 1611
页数:7
相关论文
共 50 条
  • [1] The Prevalence of Drug-Drug Interactions with Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Patients in the Intensive Care Unit
    Johnston, Jackie P.
    Heavner, Mojdeh S.
    Liu, Michael
    Casal, Gianna Lauren H.
    Akgun, Kathleen M.
    JOURNAL OF PHARMACY PRACTICE, 2023, 36 (02) : 322 - 328
  • [2] Intensive care of human immunodeficiency virus-infected patients during the era of highly active antiretroviral therapy
    Morris, A
    Creasman, J
    Turner, J
    Luce, JM
    Wachter, RM
    Huang, L
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 166 (03) : 262 - 267
  • [3] Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy
    Singh, N
    Berman, SM
    Swindells, S
    Justis, JC
    Mohr, JA
    Squier, C
    Wagener, MM
    CLINICAL INFECTIOUS DISEASES, 1999, 29 (04) : 824 - 830
  • [4] Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients
    Turner, BJ
    JOURNAL OF INFECTIOUS DISEASES, 2002, 185 : S143 - S151
  • [5] Improving outcome of human immunodeficiency virus-infected patients in a Mexican intensive care unit
    Vargas-Infante, Yetlanezi A.
    Guerrero, M. Lourdes
    Ruiz-Palacios, Guillermo M.
    Soto-Ramirez, Luis E.
    Del Rio, Carlos
    Carranza, Jorge
    Dominguez-Cherit, Guillermo
    Sierra-Madero, Juan G.
    ARCHIVES OF MEDICAL RESEARCH, 2007, 38 (08) : 827 - 833
  • [6] Pharmacological Considerations in Human Immunodeficiency Virus-Infected Adults in the Intensive Care Unit
    DeFreitas, Ashley A.
    D'Souza, Theresa-Lynda M.
    Lazaro, Ginille J.
    Windes, Emily M.
    Johnson, Melissa D.
    Relf, Michael V.
    CRITICAL CARE NURSE, 2013, 33 (02) : 46 - 56
  • [7] Antiretroviral hepatotoxicity in human immunodeficiency virus-infected patients
    Hernandez, LV
    Gilson, I
    Jacobson, J
    Affi, A
    Puetz, TR
    Dindzans, VJ
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (10) : 1627 - 1632
  • [8] Survival of HIV-infected patients admitted to the intensive care unit in the era of highly active antiretroviral therapy
    Adlakha, A.
    Pavlou, M.
    Walker, D. A.
    Copas, A. J.
    Dufty, N.
    Batson, S.
    Edwards, S. G.
    Singer, M.
    Miller, R. F.
    INTERNATIONAL JOURNAL OF STD & AIDS, 2011, 22 (09) : 498 - 504
  • [9] Pulmonary hypertension in human immunodeficiency virus-infected patients: The role of antiretroviral therapy
    Olalla, Julian
    Urdiales, Daniel
    Pombo, Marta
    del Arco, Alfonso
    de la Torre, Javier
    Luis Prada, Jose
    MEDICINA CLINICA, 2014, 142 (06): : 248 - 252
  • [10] External ophthalmoplegia in human immunodeficiency virus-infected patients receiving antiretroviral therapy
    Pineles, Stacy L.
    Demer, Joseph L.
    Holland, Gary N.
    Ransome, Susan S.
    Bonelli, Laura
    Velez, Federico G.
    JOURNAL OF AAPOS, 2012, 16 (06): : 529 - 533